Literature DB >> 12595486

Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia.

Hideyuki Arimitsu1, Kaoru Inoue, Yoshihiko Sakaguchi, Jaechul Lee, Yukako Fujinaga, Toshihiro Watanabe, Tohru Ohyama, Robert Hirst, Keiji Oguma.   

Abstract

Clostridium botulinum serotype B toxins 12S and 16S were separated by using a beta-lactose gel column at pH 6.0; toxin 12S passed through the column, whereas toxin 16S bound to the column and eluted with lactose. The fully activated neurotoxin was obtained by applying the trypsin-treated 16S toxin on the same column at pH 8.0; the neurotoxin passed through the column, whereas remaining nontoxic components bound to the column. The toxicity of this purified fully activated neurotoxin was retained for a long period by addition of albumin in the preparation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595486      PMCID: PMC148869          DOI: 10.1128/IAI.71.3.1599-1603.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes.

Authors:  Y Fujinaga; K Inoue; T Nomura; J Sasaki; J C Marvaud; M R Popoff; S Kozaki; K Oguma
Journal:  FEBS Lett       Date:  2000-02-11       Impact factor: 4.124

Review 2.  Therapeutic uses of botulinum toxin.

Authors:  J Jankovic; M F Brin
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

3.  Molecular construction of Clostridium botulinum type C progenitor toxin and its gene organization.

Authors:  Y Fujinaga; K Inoue; S Shimazaki; K Tomochika; K Tsuzuki; N Fujii; T Watanabe; T Ohyama; K Takeshi; K Inoue
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

4.  Purification and some properties of progenitor toxins of Clostridium botulinum type B.

Authors:  S Kozaki; S Sakaguchi; G Sakaguchi
Journal:  Infect Immun       Date:  1974-10       Impact factor: 3.441

5.  Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes.

Authors:  S Sugii; I Ohishi; G Sakaguchi
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

6.  The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.

Authors:  M F Lew; A Brashear; S Factor
Journal:  Neurology       Date:  2000       Impact factor: 9.910

7.  Clostridium botulinum type A haemagglutinin-positive progenitor toxin (HA(+)-PTX) binds to oligosaccharides containing Gal beta1-4GlcNAc through one subcomponent of haemagglutinin (HA1).

Authors:  Kaoru Inoue; Yukako Fujinaga; Koichi Honke; Hideyuki Arimitsu; Nazira Mahmut; Yoshihiko Sakaguchi; Tohru Ohyama; Toshihiro Watanabe; Katsuhiro Inoue; Keiji Oguma
Journal:  Microbiology       Date:  2001-04       Impact factor: 2.777

8.  Characterization of nontoxic-nonhemagglutinin component of the two types of progenitor toxin (M and L) produced by Clostridium botulinum type D CB-16.

Authors:  T Ohyama; T Watanabe; Y Fujinaga; K Inoue; H Sunagawa; N Fujii; K Inoue; K Oguma
Journal:  Microbiol Immunol       Date:  1995       Impact factor: 1.955

9.  Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence.

Authors:  S M Whelan; M J Elmore; N J Bodsworth; J K Brehm; T Atkinson; N P Minton
Journal:  Appl Environ Microbiol       Date:  1992-08       Impact factor: 4.792

10.  Stabilization of botulinum toxin type A during lyophilization.

Authors:  M C Goodnough; E A Johnson
Journal:  Appl Environ Microbiol       Date:  1992-10       Impact factor: 4.792

View more
  6 in total

1.  Crystal structure of Clostridium botulinum whole hemagglutinin reveals a huge triskelion-shaped molecular complex.

Authors:  Sho Amatsu; Yo Sugawara; Takuhiro Matsumura; Kengo Kitadokoro; Yukako Fujinaga
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

2.  Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.

Authors:  R Zichel; A Mimran; A Keren; A Barnea; I Steinberger-Levy; D Marcus; A Turgeman; S Reuveny
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

3.  PEG precipitation coupled with chromatography is a new and sufficient method for the purification of botulinum neurotoxin type B [corrected].

Authors:  Yao Zhao; Lin Kang; Shan Gao; Xing Gao; Wenwen Xin; Jinglin Wang
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

4.  Application of purified botulinum type a neurotoxin to treat experimental trigeminal neuropathy in rats and patients with urinary incontinence and prostatic hyperplasia.

Authors:  Yoshizo Matsuka; Teruhiko Yokoyama; Yumiko Yamamoto; Tomonori Suzuki; Ni Nengah Dwi Fatmawati; Atsushi Nishikawa; Tohru Ohyama; Toshihiro Watanabe; Takuo Kuboki; Atsushi Nagai; Keiji Oguma
Journal:  J Toxicol       Date:  2012-06-14

5.  Simple method for Shiga toxin 2e purification by affinity chromatography via binding to the divinyl sulfone group.

Authors:  Hideyuki Arimitsu; Keiko Sasaki; Hiroe Kojima; Tadashi Yanaka; Takao Tsuji
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

6.  Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.

Authors:  Takuhiro Matsumura; Sho Amatsu; Ryo Misaki; Masahiro Yutani; Anariwa Du; Tomoko Kohda; Kazuhito Fujiyama; Kazuyoshi Ikuta; Yukako Fujinaga
Journal:  Toxins (Basel)       Date:  2020-05-07       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.